Cardiovascular Cascade Genetic Testing: Exploring the Role of Direct Contact and Technology by Amy C. Sturm
April 2016 | Volume 3 | Article 111
OpiniOn
published: 19 April 2016
doi: 10.3389/fcvm.2016.00011
Frontiers in Cardiovascular Medicine | www.frontiersin.org
Edited by: 
Matteo Vatta, 
Indiana University, USA
Reviewed by: 
Michiel Rienstra, 
University Medical Center 
Groningen, Netherlands
*Correspondence:
Amy C. Sturm  
amy.sturm@osumc.edu
Specialty section: 
This article was submitted to 
Cardiovascular Genetics 
and Systems Medicine, 
a section of the journal 
Frontiers in Cardiovascular Medicine
Received: 22 February 2016
Accepted: 05 April 2016
Published: 19 April 2016
Citation: 
Sturm AC (2016) Cardiovascular 
Cascade Genetic Testing: Exploring 
the Role of Direct Contact 
and Technology. 
Front. Cardiovasc. Med. 3:11. 
doi: 10.3389/fcvm.2016.00011
Cardiovascular Cascade Genetic 
Testing: Exploring the Role of Direct 
Contact and Technology
Amy C. Sturm1,2*
1 Department of Internal Medicine, Division of Human Genetics, Ohio State University Wexner Medical Center, Columbus, 
OH, USA, 2 Ohio State University Wexner Medical Center, Dorothy M. Davis Heart and Lung Research Institute, 
Columbus, OH, USA
Keywords: direct contact, cardiovascular genetics, familial hypercholesterolemia, genetic counselor, 
genetic counseling, cascade screening, cascade testing, genetic testing
Cascade screening is one of the more forceful demonstrations that molecular biology and 
genetics are not just a tool for researchers, but represent an important and by now essential 
component of good medical care.
– Peter J. Schwartz (1)
inTRODUCTiOn
There is much attention and excitement in the current health care environment on the potential 
of precision medicine based on a patient’s genomic data. Today, what arguably remains as one of 
the most valuable and informative genetic tests is that of predictive testing for a known familial 
pathogenic variant. Predictive genetic testing determines whether the pathogenic variant previously 
identified in an affected family member(s) is present or not in relatives at risk. Previous research has 
documented that affected individuals undergoing genetic testing cite obtaining genetic information 
for others as being the most important, if not the only, motivation for undergoing genetic testing 
(2). Predictive, cascade testing is able to separate at-risk relatives who require vigilant serial screen-
ing from those who do not. For those with the predisposition, clinical screening allows for early 
identification of the family’s phenotype, which when present, may require lifelong medical therapy, 
implantation of devices, and/or other types of medical management. Relatives who test negative 
for the familial variant can typically be released from lifelong screening. In addition, it is also then 
known that their children are not at increased risk for the family’s disease. This approach can save 
the health care system, and the family itself, thousands of dollars. Cascade screening is imperative 
with “high-stakes” cardiovascular conditions, such as familial hypercholesterolemia (FH), long 
QT syndrome (LQTS), and other inherited arrhythmias, as well as other heritable cardiovascular 
phenotypes, including cardiomyopathies and aneurysms, where there is an increased risk for sudden 
cardiac death and severe morbidities such as heart failure.
The value of cascade screening for highly penetrant cardiovascular (and cancer) phenotypes has 
been acknowledged by public health officials. The United States Centers for Disease Control Office 
of Public Health Genomics classifies cascade screening of at-risk relatives for certain conditions, 
FH being one, as a Tier 1 genomic application, meaning it meets the criteria for analytic and clini-
cal validity and utility and therefore has evidence supporting its implementation into practice (3). 
Cascade screening may include targeted genetic testing as well as clinical screening (e.g., lipid panel) 
of at-risk relatives.
This opinion provides a brief summary of research in this area and poses questions to facilitate 
future discussion regarding the potential for direct contact of at-risk relatives. As a practicing genetic 
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counselor in clinical genetic medicine for 14  years who has 
provided genetic counseling and testing to thousands of families 
with heritable cardiovascular and cancer conditions, it is my 
opinion that more could be done to provide assistance to probands 
for at-risk relative notification and that genetic counselors are in 
the ideal position to facilitate cascade testing and lead forward-
thinking research in this area (4).
CASCADE SCREEninG: WHERE  
ARE WE nOW?
Cascade screening is a mechanism for identifying people at risk 
for a genetic condition by a process of systematic family tracing. 
It should begin with first-degree relatives (parents, siblings, and 
children) and then extend to second- and third-degree relatives 
in a stepwise, cascade fashion, moving through the pedigree in 
sequential steps as additional family members are diagnosed until 
all at-risk relatives have been screened (5). Cascade screening for 
FH is a cost-effective method for identifying new cases of FH 
(6–8). Cascade screening in families with inherited arrhythmia 
syndromes has been shown to lead to immediate prophylactic 
treatment, including drug treatment or implantation of pacemak-
ers or cardioverter defibrillators (9). However, cascade screening 
is not effective unless at-risk relatives are first notified of their risk, 
the health implications of the inherited condition in their family, 
the availability of testing, with subsequent uptake. However, 
uptake of genetic counseling and predictive genetic testing has 
been shown to be inadequate (10). While there is support from 
payers, public health, and health care providers (HCPs) regarding 
the importance of cascade testing, how best to inform relatives of 
their risk and systematically implement cascade testing has yet to 
be determined.
Psychological, educational, geographical, and other barri-
ers exist to family communication of genetic risk information. 
Ethical factors and family dynamics, including maintenance of 
confidentiality and privacy, potential for psychological harm and 
genetic discrimination (i.e., life insurance), balancing the right 
“not to know” with “duty to warn,” among others, must be con-
sidered (11). The currently recommended approach for FH, made 
by the International FH Foundation, includes the following: (1) 
the proband’s HCP should construct a pedigree that facilitates 
identification of at-risk relatives who should be offered testing; 
(2) the HCP should discuss risk notification with the proband; 
and (3) the proband should be provided with written information 
that includes general information about the family’s condition, 
the benefit, and availability of preventive therapies, emphasizes 
health consequences without testing, and be encouraged to share 
this with relatives (12). This approach should be taken with 
other highly penetrant autosomal dominant conditions. In one 
study specific to inherited arrhythmias and cardiomyopathies, 
probands were asked to distribute “family letters” containing 
information on risks, genetic and other screening tests, and pre-
ventive options to relatives at risk. In this study, 57% of informed 
relatives underwent screening (80% in arrhythmia families; 45% 
in cardiomyopathy families), and this was statistically significant 
when compared to the group where no family letter was provided 
(35%). While such “family letters” increased the number of rela-
tives who presented for evaluation, over 50% in cardiomyopathy 
families and 43% overall of at-risk relatives had no documenta-
tion that they underwent cascade evaluation (13).
It has been suggested that it is not outrageous to expect that 
clinicians, once they have diagnosed a patient with a genetic 
arrhythmia, “track down” all at-risk family members and 
determine their genetic status (1). However, realistically, imple-
mentation of this approach is problematic since many health care 
systems do not support this type of family-centric care model. 
Specifically, a recent review presents health policy-related limita-
tions faced in the United States to effective implementation of 
cascade screening and includes (1) a low rate of reimbursement 
for comprehensive genetic counseling services; (2) an individual, 
versus family-centric, approach to prevention and insurance cov-
erage; (3) insufficient genetic risk assessment and knowledge by a 
majority of HCPs without genetics credentials; and (4) a shortage 
of genetics specialists (in rural areas especially) (14). In order 
to begin addressing and overcoming these challenges, research 
should be conducted demonstrating effectiveness of novel meth-
ods and tools that have the capacity to efficiently notify relatives 
of risk. These tools should provide education, offer support, and 
provide attainable next steps with calls to action so that probands 
can be assisted, and their relatives can understand their own risk 
and be supported to act on it.
DiRECT COnTACT in CASCADE 
SCREEninG: SHOULD WE TAKE A  
MORE ACTiVE AppROACH?
Different methods of informing relatives of risk exist including 
(1) proband, or family-mediated, contact; (2) proband, or family-
mediated, contact with assistance (provision of materials, such as 
a family letter or other written information aids, by the HCP to 
the proband); and (3) direct contact of at-risk relatives by the 
clinical service itself.
Research suggests that clinical providers may take an active 
approach and directly contact relatives to notify them of their risk 
without compromising privacy or autonomy, with significantly 
higher numbers of relatives whose genetic status is clarified for 
greater efficiency, and with high levels of acceptability (15–18). A 
thematic analysis of FH proband interviews found that probands 
believed they had insufficient authority or control to persuade 
family members to attend screening and that they welcomed 
greater assistance from the clinic for contact with relatives 
(19). Also in support of direct contact is increased accuracy, as 
errors may occur in proband-mediated transmission of genetic 
testing result information through families (20). However, a 
prior study found that FH patients who expressed a preference 
regarding cascading method favored indirect contact because 
they considered it less threatening to family members (21). A 
genetic counseling intervention study that offered direct contact 
to the index patient as a last option for assistance in informing 
at-risk relatives reported no uptake; only eight index patients 
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were offered this service, however, and none of the patients in 
this study had cardiovascular phenotypes (22). A recent literature 
review concluded that most studies support direct contact of 
relatives via letter mailed from the provider and that provider-
initiated communication more often resulted in relatives being 
tested compared to other methods of communication (16).
Regarding additional Tier 1 conditions, a prospective study 
of families with BRCA mutations associated with Hereditary 
Breast Ovarian Cancer syndrome compared proband-mediated 
contact to a direct contact intervention protocol that included 
a letter and subsequent phone call to at-risk relatives (17). 
This study concluded that the direct contact protocol nearly 
doubled the number of relatives tested and was also found 
to be psychologically safe. A direct contact study in families 
with Lynch syndrome, or hereditary non-polyposis colorectal 
cancer, demonstrated high approval in those who consented to 
participate, with a third of newly diagnosed mutation carriers 
having cancer identified in their first post-test colonoscopy. 
This type of data demonstrates acceptability of direct contact 
risk notification programs, as well as efficacy, feasibility, and also 
ethical responsibility.
From the perspective of those potentially at risk, a study con-
ducted in Australia assessing community members’ viewpoints 
showed that over 90% of respondents indicated their desire to be 
informed about a familial risk of FH and to be offered screening, 
with evidence of strong community support for direct contact by 
an FH clinic (23). The “right to know” must also be considered.
FUTURE DiRECTiOnS
Research evaluating genetic counseling interventions focused on 
strengthening family communication, the number of relatives 
informed of risk, and the impact on uptake of genetics services 
is ongoing and will help inform future efforts (22, 24). A rand-
omized controlled trial studying whether a specifically designed 
genetic counseling intervention that included telephone support 
up to three times post new genetic diagnosis showed no overall 
significant difference for the level of family communication 
between the intervention and control groups (25). In this study, 
the level of family communication was the highest for condi-
tions with appropriate treatments or active surveillance, such as 
LQTS and hypertrophic cardiomyopathy. While promising, the 
level still only reached ~30%. These data again beg the question 
regarding the potential role for direct contact, especially in “high 
stakes” conditions.
Most, if not all, of the research conducted to date specific to 
direct contact has been done outside the United States. Therefore, 
there is a real need for research to determine whether direct con-
tact methods would be acceptable to probands, at-risk relatives, 
and HCPs within the United States. How many probands might 
indeed welcome and appreciate this assistance and support and 
opt in to programs that work with and/or for them to assist in 
disclosure of risk information to relatives? This opinion piece 
does not propose that we break probands’ confidentiality and 
throw privacy to the wind. Instead, it hopes to promote additional 
conversation and brainstorming that may lead to the develop-
ment and testing of innovative models of care for probands with 
highly penetrant, yet manageable conditions. The ultimate goal is 
that we will have greater impact in our work with these families 
where there are clear risk-reducing interventions. Probands and 
family members should be engaged in shaping these models and 
the research testing them, starting now!
The next question becomes, what is feasible now in the land-
scape of our current health care system? Can we systematize the 
collection of informed consent from probands to directly share 
their protected health information with relatives for which they 
provide the clinic contact information? Can we offer probands 
active assistance in family communication of genetic risk infor-
mation? In the pediatric setting, is there a role for standardized 
direct contact of HCPs caring for the at-risk children in our 
pedigrees with FH, other Tier One conditions, and beyond? 
This may be a service welcomed by the affected parent proband, 
who may appreciate greater assistance in coordination of care 
for their at-risk children and other pediatric members of their 
family.
Advances in web-based technologies and novel models for 
the delivery of genetic counseling may be able to bring cascade 
testing more effectively and efficiently to larger numbers of at-risk 
relatives. For example, home-based online genetic counseling 
sessions for cardiovascular genetic cascade screening can be 
effective (26), allowing at-risk individuals to access their genetic 
risk information at the time of their choosing and without having 
to travel to a hospital or clinic, a barrier mentioned previously. 
In addition, interactive e-learning and decisional support e-tools 
available via informative websites and mobile applications have 
been used in pre-test genetic counseling with high knowledge and 
satisfaction, leading toward the “e-informed” patient (27). Mobile 
health applications have been shown to result in more “activated” 
patients – defined as individuals who believe their roles are impor-
tant, that they have the confidence and knowledge needed to take 
action, and that they can engage in health-promoting behaviors 
(28), such as predictive genetic testing. Probands with higher 
activation may lead toward more at-risk relatives notified of their 
risk. In turn, e-learning information, such as an informational 
video about the family’s inherited cardiovascular disease, could 
then be delivered to relatives, who may then become activated 
themselves to pursue cascade testing.
The power of preventive genetic and genomic information is 
real – that is not the question. How to ensure this information 
gets into the hands of all that need it, including children, however, 
needs more active attention.
In conclusion, a powerful quote from Newson and Humphries 
(11): “Our biology does not stop: the risk of developing coronary 
heart disease as a consequence of FH will still be present, even if 
relatives live in ignorance.”
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